Article
Swedish Supplements Manufacturer Wellma Explores Options via Jefferies
Investment firm Systematic Growth has hired sell-side Jefferies to explore options for its Swedish production of food supplements, nutraceuticals and pharmaceuticals company Wellma, sources told Octus.
The business’ projected EBITDA for 2025 is around €40 million, according to sources. Wellma has reported annual sales of over €120 million, according to a company announcement in April this year.
Deals in the healthcare equipment sector in Europe trade at an average multiple of 12.24x pro forma EBITDA (pre-IFRS 16), according to Fundamentals by Octus.
Founded in 2021 by Systematic Growth, Wellma specializes in the development and production of nutraceuticals and pharmaceuticals with production sites across Europe and a global customer base. The group produces over 5 billion doses annually, its website shows.
Jefferies and Systematic Growth declined to comment.
This publication has been prepared by Octus Intelligence, Inc. or one of its affiliates (collectively, "Octus") and is being provided to the recipient in connection with a subscription to one or more Octus products. Recipient’s use of the Octus platform is subject to Octus Terms of Use or the user agreement pursuant to which the recipient has access to the platform (the “Applicable Terms”). The recipient of this publication may not redistribute or republish any portion of the information contained herein other than with Octus express written consent or in accordance with the Applicable Terms. The information in this publication is for general informational purposes only and should not be construed as legal, investment, accounting or other professional advice on any subject matter or as a substitute for such advice. The recipient of this publication must comply with all applicable laws, including laws regarding the purchase and sale of securities. Octus obtains information from a wide variety of sources, which it believes to be reliable, but Octus does not make any representation, warranty, or certification as to the materiality or public availability of the information in this publication or that such information is accurate, complete, comprehensive or fit for a particular purpose. Recipients must make their own decisions about investment strategies or securities mentioned in this publication. Octus and its officers, directors, partners and employees expressly disclaim all liability relating to or arising from actions taken or not taken based on any or all of the information contained in this publication. © 2026 Octus. All rights reserved. Octus(TM) and the Octus logo are trademarks of Octus Intelligence, Inc.